Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) FCF Margin (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed FCF Margin for 15 consecutive years, with 10.29% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin fell 1326.0% year-over-year to 10.29%; the TTM value through Mar 2026 reached 15.62%, down 1021.0%, while the annual FY2025 figure was 18.62%, 1043.0% down from the prior year.
  • FCF Margin hit 10.29% in Q1 2026 for Corcept Therapeutics, down from 19.0% in the prior quarter.
  • Across five years, FCF Margin topped out at 42.78% in Q3 2023 and bottomed at 10.29% in Q1 2026.
  • Average FCF Margin over 5 years is 23.61%, with a median of 24.89% recorded in 2024.
  • Year-over-year, FCF Margin plummeted -3085bps in 2022 and then skyrocketed 2887bps in 2024.
  • Corcept Therapeutics' FCF Margin stood at 32.37% in 2022, then crashed by -87bps to 4.08% in 2023, then soared by 707bps to 32.95% in 2024, then crashed by -42bps to 19.0% in 2025, then tumbled by -154bps to 10.29% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 10.29%, 19.0%, and 26.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.